Sema4 Holdings Corp

GeneDx Holdings Corp. is a patient centered health intelligence company. It engages in transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. The firm, through its Centrellis health intelligence platform, generates a more complete understanding of disease and wellness and provides science-driven solutions to the most pressing medical needs. The company was founded by Eric Schadt in October 2015 and is headquartered in Stamford, CT.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN FRANCISCO , Sept. 9, 2022 /PRNewswire/ -- Hagens Berman urges Sema4 Holdings Corp. (NASDAQ: SMFR) investors who suffered significant losses to submit your losses now.

SMFR INVESTOR ALERT: Hagens Berman, National Trial Attorneys, Encourages Sema4 Holdings (SMFR) Investors with Significant Losses to Contact the Firm's Attorneys, Securities Fraud Class Action Filed

NEW YORK--(BUSINESS WIRE)-- #Action--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Sema4 Holdings Corp. (“Sema4” or the “Company”) (NASDAQ: SMFR, SMFRW) in the United States District Court for the District of Connecticut on behalf of all persons and entities who purchased or otherwise acquired Sema4 securities between March 14, 2022 and August 15, 2022, both dates inclusive (the “Class Period”). Investors

SEMA4 ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Sema4 Holdings Corp. and Encourages Investors to Contact the Firm

SAN DIEGO--(BUSINESS WIRE)---- $SMFA #AI--Sema4 Holdings Corp. (SMFR) Failed to Disclose it was Experiencing Declining Selling Prices for its Reproductive Health Segment

Sema4 Holdings Corp. Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Sema4 Holdings Corp. (SMFR)

San Diego, California--(Newsfile Corp. - September 8, 2022) - Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Sema4 Holdings Corp. (NASDAQ: SMFR) (NASDAQ: SMFRW) securities between March 14, 2022 and August 15, 2022, inclusive (the "Class Period") have until November 7, 2022 to seek appointment as lead plaintiff. The Sema4 class action lawsuit - captioned Helo v. Sema4 Holdings Corp., No. 22-cv-01131 (D. Conn.

INVESTOR ALERT: Sema4 Holdings Corp. Investors with Substantial Losses Have Opportunity to Lead the Sema4 Class Action Lawsuit - SMFR; SMFRW

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Sema4 Holdings Corp. (“Sema4” or the “Company”) (NASDAQ: SMFR, SMFRW) securities between March 14, 2022 and August 15, 2022, inclusive (the “Class Period”). Sema4 investors have until November 7, 2022 to file a lead plaintiff motion. Investors suffering losses on their Sema4 investments are encouraged to contact the Law Offices of Howard G. Smi

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Sema4 Holdings Corp. (SMFR, SMFRW) Investors

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), announces that it has filed a class action lawsuit in the United States District Court for the District of Connecticut, captioned Helo v. Sema4 Holdings Corp., et al., Case No. 22-cv-01131, on behalf of persons and entities that purchased or otherwise acquired Sema4 Holdings Corp. (“Sema4” or the “Company”) (NASDAQ: SMFR, SMFRW) securities between March 14, 2022 and August 15, 2022, inclusive (the “Class Period”). Plaintiff

SMFR, SMFRW CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Sema4 Holdings Corp.

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Sema4 To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - September 6, 2022) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Sema4 Holdings Corp. ("SMFR" or the "Company") (NASDAQ: SMFR, SMFRW).If you suffered losses exceeding $50,000 investing in Sema4 stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Sema4 Investor Alert

Los Angeles, California--(Newsfile Corp. - September 1, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sema4 Holdings Corp. ("Sema4" or "the Company") (NASDAQ: SMFR) (NASDAQ: SMFRW) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

ONGOING INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Sema4 Holdings Corp. with Losses of $100,000 to Contact the Firm

Los Angeles, California--(Newsfile Corp. - August 29, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sema4 Holdings Corp. ("Sema4" or "the Company") (NASDAQ: SMFR) (NASDAQ: SMFRW) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Sema4 Holdings Corp. with Losses of $100,000 to Contact the Firm

Los Angeles, California--(Newsfile Corp. - August 26, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sema4 Holdings Corp. ("Sema4" or "the Company") (NASDAQ: SMFR) (NASDAQ: SMFRW) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Sema4 Holdings Corp. with Losses of $100,000 to Contact the Firm

Mr. Feeley, former CFO of GeneDx and BioReference Laboratories, will focus on further building profitable growth, efficiency, and scale at Sema4 Mr. Feeley, former CFO of GeneDx and BioReference Laboratories, will focus on further building profitable growth, efficiency, and scale at Sema4

Sema4 Appoints Healthcare and Diagnostics Industry Veteran Kevin Feeley as Chief Financial Officer

Los Angeles, California--(Newsfile Corp. - August 24, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sema4 Holdings Corp. ("Sema4" or "the Company") (NASDAQ: SMFR) (NASDAQ: SMFRW) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Sema4 Holdings Corp. with Losses of $100,000 to Contact the Firm

Los Angeles, California--(Newsfile Corp. - August 23, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sema4 Holdings Corp. ("Sema4" or "the Company") (NASDAQ: SMFR) (NASDAQ: SMFRW) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

ONGOING INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Sema4 Holdings Corp. with Losses of $100,000 to Contact the Firm

San Francisco, California--(Newsfile Corp. - August 22, 2022) - Hagens Berman urges Sema4 Holdings Corp. (NASDAQ: SMFR) investors who suffered significant losses to submit your losses now.Visit: www.hbsslaw.com/investor-fraud/SMFRContact An Attorney Now: SMFR@hbsslaw.com844-916-0895Sema4 Holdings Corp. (NASDAQ: SMFR) Investigation: The investigation focuses on Sema4's billing practices and reported revenues.In past quarters, Sema4 has touted its improved revenue collection efforts, claiming these and other initiatives would allow the company to

SMFR INVESTIGATION: Hagens Berman, National Trial Attorneys, Encourages Sema4 Holdings (SMFR) Investors with Significant Losses to Contact the Firm's Attorneys, Firm Investigating Possible Securities Law Violations

Los Angeles, California--(Newsfile Corp. - August 22, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sema4 Holdings Corp. ("Sema4" or "the Company") (NASDAQ: SMFR) (NASDAQ: SMFRW) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

ONGOING INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Sema4 Holdings Corp. with Losses of $100,000 to Contact the Firm

NEW YORK--(BUSINESS WIRE)-- #Action--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Sema4 Holdings Corp. (“Sema4” or the “Company”) (NASDAQ: SMFR, SMFRW) on behalf of Sema4 stockholders. Our investigation concerns whether Sema4 has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On July 22, 2021, CM Life Sciences, Inc., a special purpose acqui

SEMA4 ALERT: Bragar Eagel & Squire, P.C. is Investigating Sema4 Holdings Corp. on Behalf of Sema4 Stockholders and Encourages Investors to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Sema4 Holdings Corp. (“Sema4” or the “Company”) (NASDAQ: SMFR, SMFRW) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Sema4 investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securiti

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Sema4 Holdings Corp. (SMFR, SMFRW) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Sema4 Holdings Corp. (“Sema4” or the “Company”) (NASDAQ: SMFR, SMFRW) investors concerning the Company's possible violations of federal securities laws. On July 22, 2021, CM Life Sciences, Inc., a special purpose acquisition company, completed its business combination with Mount Sinai Genomics, Inc., and the combined public entity was renamed Sema4. Less than a year later, on June 14, 2022, Se

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Sema4 Holdings Corp. (SMFR, SMFRW) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Sema4 Holdings Corp. (“Sema4” or the “Company”) (NASDAQ: SMFR, SMFRW) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On July 22, 2021, CM Life Sciences, Inc., a special purpose acquisition company, completed its business combination with Mount Sinai Genomics, Inc., and the combined p

The Law Offices of Frank R. Cruz Announces Investigation of Sema4 Holdings Corp. (SMFR, SMFRW) on Behalf of Investors

The healthcare company delivered plenty of bad news in its Q2 update.

Why Sema4 Holdings Stock Is Crashing Today

Sema4 Holdings Corp (NASDAQ:SMFR ) Q2 2022 Earnings Conference Call August 15, 2022 4:30 PM ET Company Participants Joel Kaufman - VP, Finance & Corporate Development Katherine Stueland - CEO & Director Kevin Feeley - SVP, Operations and Head of GeneDx Conference Call Participants David Delahunt - Goldman Sachs Group Matt Kim - Jeffrey Max Masucci - Cowen and Company Mark Massaro - BTIG Operator Good day, and thank you for standing by. Welcome to the Sema4 Second Quarter 2022 Earnings Conference Call.

Sema4 Holdings Corp (SMFR) CEO Katherine Stueland on Q2 2022 Results - Earnings Call Transcript

Big data and machine learning are booming also in healthcare, where it enables precision medicine and population health platform services. Sema4 Holdings has amassed huge amounts of medical data and a sophisticated platform in order to extract valuable insight from these for health systems, pharma companies and individuals.

Sema4 Holdings, Big Data For Precision Medicine Solutions

Sema4 Holdings Corp. (SMFR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Sema4 Holdings Corp. (SMFR) Moves to Buy: Rationale Behind the Upgrade

Appoints Richard Miao, Sema4's Deputy Chief Financial Officer, as interim Chief Financial Officer

Sema4 Announces Chief Financial Officer Transition Plan

The wide-ranging Avera/Sema4 Oncology and Analytics Protocol (ASAP) study is expected to enable precision oncology care for thousands of patients The wide-ranging Avera/Sema4 Oncology and Analytics Protocol (ASAP) study is expected to enable precision oncology care for thousands of patients

News for Sema4 Holdings Corp Stock (SMFR)